A Randomised, Double Blind, Placebo-controlled, Single Ascending Dose, Phase 1a/1b Multi-centre Study in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK4771261.
Latest Information Update: 10 Oct 2024
At a glance
- Drugs GSK 4771261 (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Adverse reactions; First in man
- Sponsors GSK
- 10 Oct 2024 New trial record